BlackRock Inc. Acquires 930,303 Shares of ADMA Biologics Inc (ADMA)

BlackRock Inc. grew its holdings in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 2,295.0% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 970,839 shares of the biotechnology company’s stock after acquiring an additional 930,303 shares during the quarter. BlackRock Inc.’s holdings in ADMA Biologics were worth $4,378,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Schwab Charles Investment Management Inc. purchased a new stake in shares of ADMA Biologics during the 2nd quarter valued at about $160,000. Spark Investment Management LLC raised its position in ADMA Biologics by 68.7% in the 2nd quarter. Spark Investment Management LLC now owns 37,460 shares of the biotechnology company’s stock worth $168,000 after purchasing an additional 15,260 shares during the period. JPMorgan Chase & Co. purchased a new stake in ADMA Biologics in the 1st quarter worth about $182,000. Private Advisor Group LLC purchased a new stake in ADMA Biologics in the 2nd quarter worth about $235,000. Finally, Bank of New York Mellon Corp raised its position in ADMA Biologics by 188.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 54,828 shares of the biotechnology company’s stock worth $247,000 after purchasing an additional 35,791 shares during the period. Hedge funds and other institutional investors own 55.07% of the company’s stock.

A number of analysts recently weighed in on the stock. HC Wainwright set a $17.00 price objective on shares of ADMA Biologics and gave the stock a “buy” rating in a research report on Friday. Oppenheimer set a $13.00 price objective on shares of ADMA Biologics and gave the stock a “buy” rating in a research report on Wednesday, October 17th. Maxim Group reissued a “buy” rating and issued a $12.00 price objective on shares of ADMA Biologics in a research report on Wednesday, October 17th. Raymond James reissued a “buy” rating and issued a $10.00 price objective (down from $11.00) on shares of ADMA Biologics in a research report on Friday, October 12th. Finally, BidaskClub raised shares of ADMA Biologics from a “hold” rating to a “buy” rating in a research report on Wednesday, September 5th. Eight equities research analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and a consensus target price of $11.58.

ADMA Biologics stock opened at $5.26 on Friday. The company has a debt-to-equity ratio of 0.79, a quick ratio of 8.88 and a current ratio of 10.65. ADMA Biologics Inc has a 1-year low of $2.10 and a 1-year high of $6.96. The stock has a market capitalization of $266.97 million, a P/E ratio of -2.75 and a beta of 2.28.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Thursday, November 8th. The biotechnology company reported ($0.33) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.02). ADMA Biologics had a negative return on equity of 89.78% and a negative net margin of 119.34%. The firm had revenue of $4.23 million during the quarter, compared to analysts’ expectations of $5.39 million. Sell-side analysts expect that ADMA Biologics Inc will post -1.36 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “BlackRock Inc. Acquires 930,303 Shares of ADMA Biologics Inc (ADMA)” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another site, it was illegally stolen and republished in violation of United States and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/11/11/blackrock-inc-acquires-930303-shares-of-adma-biologics-inc-adma.html.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

Featured Article: Swap

Want to see what other hedge funds are holding ADMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ADMA Biologics Inc (NASDAQ:ADMA).

Institutional Ownership by Quarter for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply